undamentalytics Newsletter
Sign in

Virax Biolabs Group Ltd revenue

Virax Biolabs Group Ltd's revenue was $12,423 in fiscal 2026, up 96.2% on the year before. Since fiscal 2021 ($123,820) it has grown at a compound -36.9% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026
Revenue12409156612
Growth on the year before—−100.0%—+>999%−96.0%+96.2%
Gross profit−9—−151−538
Gross margin−7.6%—−15.9%32.3%—61.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Virax Biolabs Group Ltd $12,423 96.2% —
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
Creative Medical Technology Holdings, Inc. $3,000 -50.0% -65.6%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —

Compare with peers

Head to head: LYEL vs VRAXCELZ vs VRAXAIM vs VRAX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Virax Biolabs Group Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Virax Biolabs Group Ltd.